rs794728631
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_001370259.2(MEN1):c.1660C>T(p.Gln554*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_001370259.2 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MEN1 | NM_001370259.2 | c.1660C>T | p.Gln554* | stop_gained | Exon 10 of 10 | ENST00000450708.7 | NP_001357188.2 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Multiple endocrine neoplasia, type 1 Pathogenic:1
ClinVar contains an entry for this variant (Variation ID: 200988). This sequence change creates a premature translational stop signal (p.Gln554*) in the MEN1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 57 amino acid(s) of the MEN1 protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with clinical features of multiple endocrine neoplasia type 1 (MEN 1) (PMID: 11578300, 17158764, 17853334, 28321559). This variant is also known as c.1770C>T. This variant disrupts the p.Ser555 amino acid residue in MEN1. Other variant(s) that disrupt this residue have been determined to be pathogenic (Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -
not provided Pathogenic:1
The Q554X nonsense mutation in the MEN1 gene has been reported previously in association with multiple endocrine neoplasia type 1 (Langer et al., 2001). This mutation is predicted to delete the last 57 amino acids of the protein, causing loss of normal protein function through protein truncation. The variant is found in MEN1 panel(s). -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.Q554* pathogenic mutation (also known as c.1660C>T), located in coding exon 9 of the MEN1 gene, results from a C to T substitution at nucleotide position 1660. This changes the amino acid from a glutamine to a stop codon within coding exon 9. This alteration occurs at the 3' terminus of theMEN1 gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 9.3% of the protein. However, premature stop codons are typically deleterious in nature and a significant portion of the protein is affected (Ambry internal data). This variant has been observed in multiple individuals with a personal and/or family history that is consistent with multiple endocrine neoplasia type 1 (Langer P et al. Br. J. Surg. 2001 Oct;88(10):1403-7; Kann PH et al. Endocr. Relat. Cancer. 2006 Dec;13(4):1195-202; Schaaf L et al. Exp. Clin. Endocrinol. Diabetes 2007 Sep;115(8):509-17; Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this variant is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at